Study characteristics
| Study (year) . | n . | Age, median (range), y . | Male, % . | Disease . | Conditioning, RI/MA, % . | Graft source, BM/PB, % . | GVHD prophylaxis . | F/U, median (range), mo . |
|---|---|---|---|---|---|---|---|---|
| Ahmed et al (2019)20,*,† | ||||||||
| Haplo | 139 | 33 (19-69) | 58 | HL | 100/0 | 70/30 | PT-Cy based | 52 (2-101) |
| MSD | 457 | 33 (18-66) | 56 | HL | 100/0 | 4/96 | CNI + (MMF 31%, MTX 48%, other 21%) | 37 (5-109) |
| Bashey et al (2016)21 | 45 (13-120) | |||||||
| Haplo | 116 | 51 (20-74) | 54 | Any | 60/40 | 55/45 | PT-Cy + Tac/MMF | |
| MSD | 181 | 53 (19-74) | 58 | Any | 46/54 | 1/99 | Tac/MTX | |
| Burroughs et al (2008)11,* | ||||||||
| Haplo | 28 | 32 (14-62) | 46 | HL | 100/0 | 100/0 | PT-Cy + Tac/MMF | 22 (4-62) |
| MSD | 38 | 33 (17-64) | 53 | HL | 100/0 | 0/100 | MMF/CNI | 24 (11-87) |
| Devillier et al (2018)17 | 26 (4-77) | |||||||
| Haplo | 33 | ≥60 | NR | AML | 100/0 | 0/100 | PT-Cy based | |
| MSD | 31 | ≥60 | NR | AML | 84/16 | 6/94 | NR | |
| Dietrich et al (2016)19,*,† | NR | |||||||
| Haplo | 59 | ≥18 | NR | NHL | 78/22 | NR | PT-Cy + (MMF/CNI 86%, CNI 5%, NR 9%) | |
| MSD | 2024 | ≥18 | NR | NHL | NR | NR | NR | |
| Dreger et al (2019)16,*,† | ||||||||
| Haplo | 132 | 58 (20-75) | 65 | DLBCL | 100/0 | 75/25 | PT-Cy ± CNI/MMF | 49 (12-73) |
| MSD | 525 | 55 (19-73) | 62 | DLBCL | 100/0 | 2/98 | CNI + (MMF 36%, MTX 45%, other 19%) | 48 (2-97) |
| Gauthier et al (2018)18,*,† | ||||||||
| Haplo | 61 | 29 (17-68) | 54 | HL | 100/0 | 51/49 | PT-Cy + CNI/MMF | 24 (3-58) |
| MSD | 90 | 32 (12-67) | 63 | HL | 100/0 | 14/86 | CNI + (none 39%, MMF 35%, MTX 25%) | 24 (3-70) |
| Ghosh et al (2016)14,*,† | ||||||||
| Haplo | 180 | 55 (18-75) | 64 | HL, NHL | 100/0 | 93/7 | PT-Cy ± CNI/MMF | 37 (6-73) |
| MSD | 807 | 54 (18-77) | 61 | HL, NHL | 100/0 | 2/98 | CNI + (MMF 31%, MTX 55%, other 14%) | 36 (3-76) |
| Martinez (2017)12 *,† | ||||||||
| Haplo | 98 | 31 (18-68) | 57 | HL | 90/10 | 61/39 | PT-Cy + CNI + (MMF 94%, other 6%) | 27 (1-64) |
| MSD | 338 | 32 (18-67) | 43 | HL | 69/31 | 10/89 | CNI + (MMF 27%, MTX 39%, other 34%) | 27 (1-76) |
| Robinson et al (2018)15,*,†,‡ | NR | |||||||
| Haplo | 218 | 41 (18-55) | 59 | AML, ALL | 40/60 | 57/43 | PT-Cy + CNI/MMF | |
| MSD | 843 | 42 (18-55) | 52 | AML, ALL | 16/84 | 12/88 | CNI + (MMF 20%, MTX 64%, none 16%) | |
| Robinson et al (2018)15,*,†,§ | NR | |||||||
| Haplo | 218 | 63 (55-76) | 59 | AML, ALL | 72/28 | 70/30 | PT-Cy + CNI/MMF | |
| MSD | 864 | 63 (55-76) | 58 | AML, ALL | 73/27 | 6/94 | CNI + (MMF 38%, MTX 45%, none 18%) | |
| Solh et al (2016)13 | 46 (12-123) | |||||||
| Haplo | 128 | 50 (19-74) | 54 | Any | 59/41 | 52/48 | PT-Cy + Tac/MMF | |
| MSD | 198 | 53 (18-77) | 59 | Any | 47/53 | 2/98 | Tac/MTX 66%, Tac/MMF 25%, other 9% |
| Study (year) . | n . | Age, median (range), y . | Male, % . | Disease . | Conditioning, RI/MA, % . | Graft source, BM/PB, % . | GVHD prophylaxis . | F/U, median (range), mo . |
|---|---|---|---|---|---|---|---|---|
| Ahmed et al (2019)20,*,† | ||||||||
| Haplo | 139 | 33 (19-69) | 58 | HL | 100/0 | 70/30 | PT-Cy based | 52 (2-101) |
| MSD | 457 | 33 (18-66) | 56 | HL | 100/0 | 4/96 | CNI + (MMF 31%, MTX 48%, other 21%) | 37 (5-109) |
| Bashey et al (2016)21 | 45 (13-120) | |||||||
| Haplo | 116 | 51 (20-74) | 54 | Any | 60/40 | 55/45 | PT-Cy + Tac/MMF | |
| MSD | 181 | 53 (19-74) | 58 | Any | 46/54 | 1/99 | Tac/MTX | |
| Burroughs et al (2008)11,* | ||||||||
| Haplo | 28 | 32 (14-62) | 46 | HL | 100/0 | 100/0 | PT-Cy + Tac/MMF | 22 (4-62) |
| MSD | 38 | 33 (17-64) | 53 | HL | 100/0 | 0/100 | MMF/CNI | 24 (11-87) |
| Devillier et al (2018)17 | 26 (4-77) | |||||||
| Haplo | 33 | ≥60 | NR | AML | 100/0 | 0/100 | PT-Cy based | |
| MSD | 31 | ≥60 | NR | AML | 84/16 | 6/94 | NR | |
| Dietrich et al (2016)19,*,† | NR | |||||||
| Haplo | 59 | ≥18 | NR | NHL | 78/22 | NR | PT-Cy + (MMF/CNI 86%, CNI 5%, NR 9%) | |
| MSD | 2024 | ≥18 | NR | NHL | NR | NR | NR | |
| Dreger et al (2019)16,*,† | ||||||||
| Haplo | 132 | 58 (20-75) | 65 | DLBCL | 100/0 | 75/25 | PT-Cy ± CNI/MMF | 49 (12-73) |
| MSD | 525 | 55 (19-73) | 62 | DLBCL | 100/0 | 2/98 | CNI + (MMF 36%, MTX 45%, other 19%) | 48 (2-97) |
| Gauthier et al (2018)18,*,† | ||||||||
| Haplo | 61 | 29 (17-68) | 54 | HL | 100/0 | 51/49 | PT-Cy + CNI/MMF | 24 (3-58) |
| MSD | 90 | 32 (12-67) | 63 | HL | 100/0 | 14/86 | CNI + (none 39%, MMF 35%, MTX 25%) | 24 (3-70) |
| Ghosh et al (2016)14,*,† | ||||||||
| Haplo | 180 | 55 (18-75) | 64 | HL, NHL | 100/0 | 93/7 | PT-Cy ± CNI/MMF | 37 (6-73) |
| MSD | 807 | 54 (18-77) | 61 | HL, NHL | 100/0 | 2/98 | CNI + (MMF 31%, MTX 55%, other 14%) | 36 (3-76) |
| Martinez (2017)12 *,† | ||||||||
| Haplo | 98 | 31 (18-68) | 57 | HL | 90/10 | 61/39 | PT-Cy + CNI + (MMF 94%, other 6%) | 27 (1-64) |
| MSD | 338 | 32 (18-67) | 43 | HL | 69/31 | 10/89 | CNI + (MMF 27%, MTX 39%, other 34%) | 27 (1-76) |
| Robinson et al (2018)15,*,†,‡ | NR | |||||||
| Haplo | 218 | 41 (18-55) | 59 | AML, ALL | 40/60 | 57/43 | PT-Cy + CNI/MMF | |
| MSD | 843 | 42 (18-55) | 52 | AML, ALL | 16/84 | 12/88 | CNI + (MMF 20%, MTX 64%, none 16%) | |
| Robinson et al (2018)15,*,†,§ | NR | |||||||
| Haplo | 218 | 63 (55-76) | 59 | AML, ALL | 72/28 | 70/30 | PT-Cy + CNI/MMF | |
| MSD | 864 | 63 (55-76) | 58 | AML, ALL | 73/27 | 6/94 | CNI + (MMF 38%, MTX 45%, none 18%) | |
| Solh et al (2016)13 | 46 (12-123) | |||||||
| Haplo | 128 | 50 (19-74) | 54 | Any | 59/41 | 52/48 | PT-Cy + Tac/MMF | |
| MSD | 198 | 53 (18-77) | 59 | Any | 47/53 | 2/98 | Tac/MTX 66%, Tac/MMF 25%, other 9% |
The study by Bashey et al21 used the National Institutes of Health consensus criteria for cGVHD grading (mild vs moderate vs severe), whereas all other studies used the original classification system (limited vs extensive).
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CNI, calcineurin inhibitor; DLBCL, diffuse large B-cell lymphoma; F/U, follow-up; Haplo, haploidentical; HL, Hodgkin lymphoma; MA, myeloablative; MMF, mycophenolate mofetil; MTX, methotrexate; NHL, non-Hodgkin lymphoma; NR, not reported; PB, peripheral blood; PT-Cy, posttransplant cyclophosphamide; RI, reduced intensity; Tac, tacrolimus.
Multicenter study.
Registry study.
Recipient age 18 to 54 years.
Recipient age ≥55 years.